Castle Biosciences, Inc.
CSTL
$38.63
$0.661.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.19% | -0.94% | 20.57% | 30.54% | 39.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.19% | -0.94% | 20.57% | 30.54% | 39.50% |
| Cost of Revenue | 19.83% | 21.40% | 17.91% | 30.27% | 37.90% |
| Gross Profit | -8.31% | -5.41% | 21.20% | 30.60% | 39.86% |
| SG&A Expenses | 10.71% | 13.66% | 20.88% | 13.33% | 13.18% |
| Depreciation & Amortization | 0.18% | -12.73% | 1,160.57% | 91.11% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.33% | 10.30% | 47.77% | 14.60% | 13.45% |
| Operating Income | -233.96% | -184.82% | -410.47% | 171.58% | 152.69% |
| Income Before Tax | -104.66% | -101.81% | -955.48% | 410.31% | 220.50% |
| Income Tax Expenses | -98.09% | -351.26% | -1,040.00% | -4,471.79% | 18,690.63% |
| Earnings from Continuing Operations | -122.08% | -49.29% | -920.05% | 471.71% | 132.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.08% | -49.29% | -920.05% | 471.71% | 132.86% |
| EBIT | -233.96% | -184.82% | -410.47% | 171.58% | 152.69% |
| EBITDA | -113.60% | -110.01% | 186.16% | 503.37% | 233.31% |
| EPS Basic | -121.10% | -51.53% | -879.93% | 457.44% | 131.68% |
| Normalized Basic EPS | -145.67% | -116.10% | -859.01% | 377.04% | 216.11% |
| EPS Diluted | -125.00% | -51.61% | -879.93% | 429.25% | 130.77% |
| Normalized Diluted EPS | -148.21% | -116.38% | -859.01% | 357.99% | 209.99% |
| Average Basic Shares Outstanding | 4.43% | 4.59% | 4.09% | 4.05% | 3.75% |
| Average Diluted Shares Outstanding | -1.12% | 2.81% | 4.09% | 11.73% | 9.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |